Safety and efficacy of mycophenolate mofetil in pediatric renal transplantation

ISRCTN ISRCTN89278733
DOI https://doi.org/10.1186/ISRCTN89278733
Secondary identifying numbers NTR800
Submission date
01/12/2006
Registration date
01/12/2006
Last edited
03/01/2008
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Urological and Genital Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Karlien Cransberg
Scientific

Erasmus Medical Center
Sophia Children's Hospital
Dr Molewaterplein 60
Rotterdam
3015 GJ
Netherlands

Phone +31 (0)10 4636363
Email k.cransberg@erasmusmc.nl

Study information

Study designRandomised, multicentre parallel armed, controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Nor ptovided at time of registration
Scientific title
Study objectives1. Mycophenolate Mofetil (MMF)/prednisolone is as efficacious in prevention of acute rejections as Cyclosporin A (CsA)/prednisolone
2. MMF/prednisolone is safer than CsA/prednisolone, in renal function, lipids, and blood pressure
Ethics approval(s)Ethics approval received from the local medical ethics committee
Health condition(s) or problem(s) studiedRenal transplant
InterventionStart trial is one year after transplantation. Randomisation between two groups: continuing with MMF/prednisolone or CsA/prednisolone by withdrawal over three months of the third immunosuppressive drug.

During the three months of withdrawal, the prednisolone dosage is doubled. Follow-up is two years.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Specified
Drug / device / biological / vaccine name(s)Mycophenolate mofetil (MMF), prednisolone and cyclosporin A (CsA)
Primary outcome measure1. Glomerular filtration rate
2. Incidence of acute rejections
3. Serum lipids
4. Blood pressure and number of antihypertensive drugs
Secondary outcome measures1. Graft survival
2. Incidence of malignancies
3. Incidence of viral infections
4. Incidence of anemia
Overall study start date01/01/2000
Completion date01/12/2005

Eligibility

Participant type(s)Patient
Age groupChild
SexNot Specified
Target number of participants44
Key inclusion criteria1. All Dutch children, receiving a first kidney transplant after 01/01/2000
2. Treated with initial immunosuppression corticosteroids, MMF and CsA, during the latter part of the study with addition of basiliximab
Key exclusion criteria1. Not on triple therapy (prednisolone/CsA/MMF) at the end of the first year
2. More than one acute rejection episode
3. Rejection episode being not steroid sensitive
4. No written informed consent
Date of first enrolment01/01/2000
Date of final enrolment01/12/2005

Locations

Countries of recruitment

  • Netherlands

Study participating centre

Erasmus Medical Center
Rotterdam
3015 GJ
Netherlands

Sponsor information

Erasmus Medical Center (The Netherlands)
Hospital/treatment centre

Sophia Children's Hospital
Dr Molewaterplein 60
Rotterdam
3015 GJ
Netherlands

Website http://www.erasmusmc.nl/
ROR logo "ROR" https://ror.org/018906e22

Funders

Funder type

Charity

Dutch Kidney Foundation (Nierstichting Nederland) (The Netherlands)
Private sector organisation / Trusts, charities, foundations (both public and private)
Alternative name(s)
Dutch Kidney Foundation
Location
Netherlands

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article Results 27/04/2007 Yes No